Neutral
Intellia Therapeutics continues to attract investor attention as it advances its CRISPR-based gene-editing pipeline. The company focuses on both in vi...
Intellia Therapeutics (NTLA) reported a Q1 2026 net loss of US$96.2 million on US$15.0 million revenue, similar to the previous quarter, raising quest...
Neutral
Intellia Therapeutics (NTLA), a clinical-stage biotech firm specializing in CRISPR-based gene editing, has seen its stock drop nearly 95% from its 202...
Bullish
Intellia Therapeutics successfully raised approximately $194.6 million through a public equity offering to fund its pipeline and operations into 2028....